Tuberculosis in the 21st Century: Challenges in Diagnosis, Treatment, and Global Control
Article Sidebar
Page Numbers:
324-330
Digital Object Identifier:
10.58578/ajcmpr.v2i2.5455
Viewed: 984 times
Downloaded: 159 times
LYAS Publisher cordially invites qualified professionals to serve as Editors or Reviewers. Your expertise will make an important contribution to maintaining and strengthening the academic quality of our publications. Interested applicants are kindly requested to complete the application form at the following link: Editors & Reviewers
Please feel free to contact us if you need any further information about the submission process or if you have any additional questions.
Authors:
Muhammad Akram1, Abid Mahmood2, Mohammed Khudhair Hasan3, Isaac John Umaru4, Hind A. Abdulghafoor5, Fahad Said Khan6, Fethi Ahmet Ozdemir7, Gaweł Sołowski8, Jaouher Ben Ali9 
Copyright :
Authors retain copyright and grant the journal right of first publication.
Main Article Content
Abstract
With an estimated 10 million cases and over one million fatalities annually, TB is still one of the most significant infectious illnesses affecting worldwide public health, mostly in low- and middle-income nations. Mainly affecting the lungs (pulmonary TB), Mycobacterium tuberculosis is a slow-growing, acid-fast bacillus that causes tuberculosis. However, it may also affect other organs, such as the lymph nodes, bones, central nervous system, and genitourinary tract. Due to a number of variables, including delayed diagnosis, poor treatment adherence, the emergence of drug-resistant strains, and socioeconomic determinants including poverty, malnutrition, and HIV co-infection, tuberculosis (TB) continues to be a major cause of morbidity and death even though it is preventable and treatable. Bacterial evasion mechanisms and the host immune response interact intricately in the pathophysiology of tuberculosis. Latent tuberculosis infection (LTBI) can result from M. tuberculosis remaining dormant in macrophages for years after inhalation. Unless they are immunocompromised, only 5–10% of infected people experience active illness at some point in their lives. Serious obstacles to tuberculosis control and eradication have arisen as a result of the development of extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB), which have further complicated treatment procedures. Although recent developments include nucleic acid amplification tests (NAATs), such as GeneXpert, and interferon gamma release assays (IGRAs) for the identification of latent infections, the diagnosis of tuberculosis still mostly depends on sputum smear microscopy, chest X-rays, and culture techniques. The necessity for novel, shorter, and more efficient medication regimens is highlighted by the fact that drug-resistant TB necessitates lengthy and sometimes hazardous second-line treatment. The BCG vaccine, early case diagnosis and treatment, and public health initiatives aimed at high-risk groups are the main components of prevention programs. Because of ongoing inequalities in health care, delayed diagnosis, and poor access to and adherence to treatment, tuberculosis eradication is still a long way off, despite international efforts through programs like the WHO's End TB Strategy.
Citation Metrics:
